|Title:||Compositions and methods for reducing ocular hypertension|
|Abstract:||An improved ophthalmic composition, including docosanoid active agents, which is especially useful in lowering intraocular pressure associated with glaucoma. Improvements in IOP reduction efficacy, preservative efficacy and reduced additive concentrations are achieved by utilizing the disclosed compositions which include a docosanoid active agent (e.g., isopropyl unoprostone), in conjunction with selected non-ionic surfactants, preservatives, and non-ionic tonicity adjusting agents.|
|Inventor(s):||Reed; Kenneth Warren (Lawrenceville, GA), Yen; Shau Fong (Atlanta, GA), Sou; Mary (Alpharetta, GA), Peacock; Regina Flinn (Alpharetta, GA)|
|Assignee:||Novartis AG (Bern, CH)|
Patent Claim Types:|
see list of patent claims
|Composition; Use; Formulation;|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Patented / Exclusive Use|
Sucampo Pharma Llc
|SOLUTION/DROPS;OPHTHALMIC||021214-001||Aug 3, 2000||DISCN||Yes||No||6,770,675||► Subscribe||Y||METHOD OF REDUCING OCULAR HYPERTENSION|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
Export unavailable in trial.
Subscribe for complete access.